ACE and cardiovascular disorder: Angiotensin-converting enzyme (ACE) inhibitor use was significantly higher among intervention group patients with known cardiovascular disease, as was sulphonylurea use among intervention group diabetic patients with BMI ≥ 30 kg/m2.